Insufficiency of timeliness and efficiency of diagnosis of malignant tumors of visual localization in the female reproductive system
https://doi.org/10.15372/SSMJ20200214
Abstract
Reproductive system cancer is the most common female malignancy, accounting for 36.1 to 37.6 % of all gynecological cancers. The incidence rate of female reproductive system cancer continues to increase. Material and methods. The study was conducted in 2018 by interviewing 391 patients with breast cancer, 273 patients with cervical cancer, 30 patients with cancer of the vulva and 11 patients with vaginal cancer were interviewed. Results. The time period for making diagnosis lasted no longer than a week in 2.0 % of respondents with breast cancer, 5.9 % with vaginal tumor and 11.3 % with cervical cancer. A long period of cancer detection was the cause of advanced cancer (56.5 and 47.0 % of cases of breast and cervical cancer, 40.0 % of vulva and 11.6 % of vaginal cancer). Discussion. The majority of district oncologists and other allied healthcare professionals are not able to identify abnormalities caused by cancer. Physicians of municipal health care facilities are either completely unaware of the procedure for routing patients with suspected malignant neoplasm or simply cannot explain it to patients. Conclusions. Oncologists working in outpatient health care facilities and other allied healthcare professionals need a special methodical literature on cancer screening. It is necessary to optimize the routing scheme of patients with suspected malignant tumors with mandatory training of oncologists and other allied healthcare professionals on the routing of such patients.
About the Authors
N. V. Voroshina
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
Russian Federation
Russian Federation
Nataliya V. Voroshina, doctor of medical sciences
454087, Chelyabinsk, Blukhera str., 42
A. V. Vazhenin
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine; South Ural State Medical University
Russian Federation
Russian Federation
Andrey V. Vazhenin, doctor of medical sciences, professor, academician of RAS
454087, Chelyabinsk, Blukhera str., 42
454092, Chelyabinsk, Vorovskogo str., 64
Yu. A. Tyukov
South Ural State Medical University
Russian Federation
Russian Federation
Yuriy A. Tyukov, doctor of medical sciences, professor
454092, Chelyabinsk, Vorovskogo str., 64
References
1. Kaprin A.D., Starinsky V.V., Petrova G.V. Malignant neoplasms in Russia in 2014 (morbidity and mortality). Moscow, 2015. 251 p. [In Russian].
2. Kaprin A.D., Starinsky V.V., Petrova G.V. Malignant neoplasms in Russia in 2015 (morbidity and mortality). Moscow, 2017. 250 p. [In Russian].
3. Kosenok V.K., Belskaya L.V., Massard Zh., Viyushkov D.M. Statistical features of breast cancer incidence in the Omsk region. Voprosy onkologii = Problems in Oncology. 2016; 62 (4): 410–415. [In Russian]. doi: 10.18722/VO2016624410-415
4. On improving the system of the state cancer registry. Order of the Ministry of Health and Social Development of the Russian Federation No. 135 04.19.99. Moscow, 1999. 153 p. [In Russian].
5. Payanidi Yu.G., Zhordania K.I., Savostikova M.V. Cervix uteri cancer: traditional and new approaches to the problem. Akusherstvo i ginekologiya = Obstetrics and Gynecology. 2015; (7): 94–99. [In Russian].
6. Schepin O.P., Petruchuk O.E., Davletshin F.A. Prevention of public health in the region. Kazan: Brig, 2010. 332 p. [In Russian].
7. Ali A.A., Richardson D., Hill N. A retrospective study of cervical screening in women under 25 years (2005-2009). Arch. Gynecol. Obstet. 2013; 287 (4): 765–769. doi: 10.1007/s00404-012-2631-9
8. Andersson M., Lidbrink E., Bjerre K., Wist E., Enevoldsen K., Jensen A.B., Karlsson P., Tange U.B., Sørensen P.G., Møller S., Bergh J., Langkjer S.T. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumabas first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J. Clin. Oncol. 2011; 29 (3): 264–271. doi: 10.1200/JCO.2010.30.8213
9. Bachelot T., Romieu G., Campone M., Diéras V., Cropet C., Dalenc F., Jimenez M., Le Rhun E., Pierga J.Y., Gonçalves A., Leheurteur M., Domont J., Gutierrez M., Curé H., Ferrero J.M., Labbe-Devilliers C. Lapatinib plus capecitabine in patients with previously untreated brain metastases from Her-2 positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013; 14 (1): 64–71. doi: 10.1016/S1470-2045(12)70432-1
10. Engholm G., Ferlay J., Christensen N., Bray F., Gjerstorff M.L., Klint A., Køtlum J.E., Olafsdóttir E., Pukkala E., Storm H.H. NORDCAN – a Nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010; 49 (5): 725–36. doi: 10.3109/02841861003782017.
11. Fеrlay J., Pаrkin D.M., Steliаrova-Fоucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer. 2010; 46 (4): 765–781. doi: 10.1016/j.ejca.2009.12.014
12. Shin H.R., Masuyer E., Ferlay J., Curado M.P. Asian Contributors to CI5 IX4. Cancer in Asia - Incidence rates based on data in cancer incidence in five continents IX (1998-2002). Asian Pac. J. Cancer Prev. 2010; 11 (Suppl. 2): 11–16.
Review
Views:
222
Email this article 